Despite notable advancements in therapeutic treatments, such as intravitreal monoclonal antibody injections targeting vascular endothelial growth factor (anti-VEGF) and/or angiopoietin-2—including Ranibizumab (Lucentis) and Aflibercept (Eylea)—retinal ischemia remains to be a challenge in the field of ophthalmology [18]. Here, VEGFA is linked to retinal ischemia.